瑞士妊娠期糖尿病管理中的持续葡萄糖监测(DipGluMo):一项开放标签、单中心、随机对照试验
该开放标签、单中心、随机对照试验纳入302例妊娠期糖尿病孕妇,比较实时持续葡萄糖监测(rtCGM)与自我血糖监测(SMBG)对围产期结局的影响。主要复合结局在两组间无显著差异(OR 1.02,95%CI 0.63-1.66)。rtCGM组皮肤改变不良事件6例(4%),SMBG组1例(<1%)。参与者对rtCGM设备偏好更高,作者认为rtCGM可提供以简化妊娠期糖尿病管理。
要点
- rtCGM与SMBG的主要围产期复合结局无显著差异(OR 1.02,95%CI 0.63-1.66)。
- rtCGM组皮肤改变6例(4%),SMBG组1例(<1%)(盲法设备)。
- 参与者对rtCGM设备偏好更高,作者认为可提供rtCGM以简化管理。
核心结论
- 研究结果显示,使用rtCGM并未改善妊娠期糖尿病个体的结局,但个体对rtCGM设备表现出更高偏好。
- 这一发现提示可提供rtCGM以简化妊娠期糖尿病管理,成本效果研究可评估哪种方法所需资源更少。
- 据作者所知,这是首个以妊娠结局评估rtCGM疗效为效能目标的随机试验。
研究设计与样本
- 开放标签、随机对照试验,于瑞士伯尔尼一家大学医院招募18-45岁符合国际糖尿病与妊娠研究组协会标准的妊娠期糖尿病孕妇。
- 参与者按1:1随机分配至rtCGM干预组或SMBG对照组,随机化基于孕前BMI、既往妊娠期糖尿病、2型糖尿病家族史和种族进行中心化分层。
- 主要终点为围产期复合结局:大于胎龄儿、巨大儿、羊水过多、新生儿低血糖和死产;关键次要结局为患者偏好和母体血糖控制;分析基于意向性治疗。
- 2021年9月29日至2024年6月11日期间,302例妊娠期糖尿病孕妇纳入研究并随机分组;rtCGM干预组156例和SMBG对照组143例完成研究。
- 297例(99%)的299例参与者有主要结局数据;试验注册号ClinicalTrials.gov NCT05037526。
主要发现
- 主要复合结局在两组间无显著差异(OR 1.02,95%CI 0.63-1.66)。
- 唯一不良事件为皮肤改变,rtCGM干预组6例(4%) vs SMBG对照组1例(<1%)(盲法设备)。
- 个体对rtCGM设备表现出更高偏好。
临床怎么用
- 作者认为,可提供rtCGM以简化妊娠期糖尿病管理。
- 作者建议,成本效果研究可评估哪种方法所需资源更少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In gestational diabetes, one of the key factors affecting perinatal outcomes is glycaemic control. We aimed to investigate the effect of real-time continuous glucose monitoring (rtCGM) on perinatal outcomes versus self-monitoring of blood glucose (SMBG). METHODS: In this open-label, randomised, controlled trial, we recruited pregnant individuals aged 18-45 years with gestational diabetes, according to the International Association of Diabetes and Pregnancy Study Groups criteria, from a university hospital in Bern, Switzerland. Participants were randomly assigned (1:1) to the rtCGM intervention group or the SMBG control group. Randomisation was done centrally on the basis of pre-pregnancy BMI, previous gestational diabetes, family history of type 2 diabetes, and ethnicity. The primary endpoint was a composite of perinatal outcomes: large for gestational age, macrosomia, polyhydramnios, neonatal hypoglycaemia, and stillbirth. Key secondary outcomes were patient preference and maternal glycaemic control. Analyses were conducted on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, NCT05037526. FINDINGS: Between Sept 29, 2021, and June 11, 2024, 302 pregnant women with gestational diabetes were included in the study and randomly assigned to one of the groups. 156 participants were assigned to the rtCGM intervention group and 143 were assigned to the SMBG control group completed the study. Primary outcome data were available for 297 (99%) of 299 participants. The composite outcome did not differ significantly between the two groups (odds ratio 1·02 [95% CI 0·63-1·66]). The only adverse events were skin changes, occurring in six (4%) participants in the rtCGM intervention group and in one (<1%) participant in the SMBG control group (blinded device). INTERPRETATION: Our results show that the outcome in individuals with gestational diabetes is not improved by the use of rtCGM. However, individuals expressed a higher preference for the rtCGM device. This finding suggests that rtCGM could be offered to simplify the management of gestational diabetes. A cost-effectiveness study could address what method requires fewer resources. To our knowledge, this is the first randomised trial powered to evaluate the efficacy of rtCGM regarding pregnancy outcomes. FUNDING: The University of Bern and the Swiss Diabetes Foundation. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
引用
- Amylidi-Mohr S, Zennaro G, Schneider S, et al. Continuous glucose monitoring in the management of gestational diabetes in Switzerland (DipGluMo): an open-label, single-centre, randomised, controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 40441173. doi:10.1016/S2213-8587(25)00063-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。